MedTrace Logo

Blue Light for Treating Psoriasis Vulgaris

NCT02004847 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2015-12-18

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the efficacy and safety of a blue light device for treating Psoriasis vulgaris. The study will compare a blue light treated plaque with an untreated control plaque. Additionally, two intensities of blue light are compared.

Conditions

  • Psoriasis Vulgaris

Interventions

DEVICE

PSO-CT02

The PSO-CT02 device is a non CE marked investigational medical device that is worn on the affected skin area where it irradiates the Psoriasis plaque for 30 minutes with blue light.

Sponsors & Collaborators

  • Philips Electronics Nederland BV

    lead INDUSTRY

Principal Investigators

  • Verena von Felbert, PD, Dr. · Clinic for Dermatology and Allergology, Medical Faculty of the RWTH Aachen, Germany

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2014-05-31
Completion
2014-05-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02004847 on ClinicalTrials.gov